Literature DB >> 29708163

Malignant pleural mesothelioma: some progress, but still a long way from cure.

Loic Lang-Lazdunski1.   

Abstract

Entities:  

Year:  2018        PMID： 29708163      PMCID： PMC5906350          DOI： 10.21037/jtd.2018.01.152

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  36 in total

1.  Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection.

Authors:  David J Sugarbaker; Ritu R Gill; Beow Y Yeap; Andrea S Wolf; Marcelo C DaSilva; Elizabeth H Baldini; Raphael Bueno; William G Richards
Journal:  J Thorac Cardiovasc Surg       Date:  2013-02-21       Impact factor: 5.209

2.  Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.

Authors:  Fauzia Shaikh; Marjorie G Zauderer; Donata von Reibnitz; Abraham J Wu; Ellen D Yorke; Amanda Foster; Weiji Shi; Zhigang Zhang; Prasad S Adusumilli; Kenneth E Rosenzweig; Lee M Krug; Valerie W Rusch; Andreas Rimner
Journal:  J Thorac Oncol       Date:  2017-03-21       Impact factor: 15.609

3.  Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.

Authors:  Gérard Zalcman; Julien Mazieres; Jacques Margery; Laurent Greillier; Clarisse Audigier-Valette; Denis Moro-Sibilot; Olivier Molinier; Romain Corre; Isabelle Monnet; Valérie Gounant; Frédéric Rivière; Henri Janicot; Radj Gervais; Chrystèle Locher; Bernard Milleron; Quan Tran; Marie-Paule Lebitasy; Franck Morin; Christian Creveuil; Jean-Jacques Parienti; Arnaud Scherpereel
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

4.  Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma.

Authors:  Dean A Fennell; Cliona McDowell; Sara Busacca; Glen Webb; Brian Moulton; Andrew Cakana; Kenneth J O'Byrne; Jan V Meerbeeck; Paul Donnellan; John McCaffrey; Paul Baas
Journal:  J Thorac Oncol       Date:  2012-09       Impact factor: 15.609

5.  In Situ Vaccination after Accelerated Hypofractionated Radiation and Surgery in a Mesothelioma Mouse Model.

Authors:  Luis De La Maza; Matthew Wu; Licun Wu; Hana Yun; Yidan Zhao; Mark Cattral; Andrea McCart; Bc John Cho; Marc de Perrot
Journal:  Clin Cancer Res       Date:  2017-06-12       Impact factor: 12.531

6.  Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma.

Authors:  Marc de Perrot; Ronald Feld; Natasha B Leighl; Andrew Hope; Thomas K Waddell; Shaf Keshavjee; B C John Cho
Journal:  J Thorac Cardiovasc Surg       Date:  2015-10-19       Impact factor: 5.209

Review 7.  Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.

Authors:  Stefan Kiesgen; Leonardo Chicaybam; Navin K Chintala; Prasad S Adusumilli
Journal:  J Thorac Oncol       Date:  2017-10-26       Impact factor: 15.609

8.  Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.

Authors:  Rolf A Stahel; Oliver Riesterer; Alexandros Xyrafas; Isabelle Opitz; Michael Beyeler; Adrian Ochsenbein; Martin Früh; Richard Cathomas; Kristiaan Nackaerts; Solange Peters; Christoph Mamot; Alfred Zippelius; Carlo Mordasini; Clemens B Caspar; Katrin Eckhardt; Ralph A Schmid; Daniel M Aebersold; Oliver Gautschi; Wolfgang Nagel; Michael Töpfer; Jerome Krayenbuehl; Karin Ribi; Ilja Ciernik; Walter Weder
Journal:  Lancet Oncol       Date:  2015-11-02       Impact factor: 41.316

9.  Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.

Authors:  Tom Treasure; Loic Lang-Lazdunski; David Waller; Judith M Bliss; Carol Tan; James Entwisle; Michael Snee; Mary O'Brien; Gill Thomas; Suresh Senan; Ken O'Byrne; Lucy S Kilburn; James Spicer; David Landau; John Edwards; Gill Coombes; Liz Darlison; Julian Peto
Journal:  Lancet Oncol       Date:  2011-06-30       Impact factor: 41.316

Review 10.  Oncolytic Viral Therapy for Mesothelioma.

Authors:  Daniel F Pease; Robert A Kratzke
Journal:  Front Oncol       Date:  2017-08-24       Impact factor: 6.244
View more
  1 in total

1.  In vitro and in vivo BNCT investigations using a carborane containing sulfonamide targeting CAIX epitopes on malignant pleural mesothelioma and breast cancer cells.

Authors:  Diego Alberti; Alessia Michelotti; Alberto Lanfranco; Nicoletta Protti; Saverio Altieri; Annamaria Deagostino; Simonetta Geninatti Crich
Journal:  Sci Rep       Date:  2020-11-06       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.